Cyclooxygenases and the cardiovascular system.
Animals
Anti-Inflammatory Agents, Non-Steroidal
/ pharmacology
Aspirin
/ pharmacology
Brain
/ drug effects
Cardiovascular Physiological Phenomena
Cardiovascular System
/ drug effects
Cyclooxygenase 1
/ metabolism
Cyclooxygenase 2
/ metabolism
Cyclooxygenase Inhibitors
/ pharmacology
Drug Stability
Endothelial Cells
/ metabolism
Humans
Hydrogen-Ion Concentration
Kidney
/ drug effects
Prostaglandin-Endoperoxide Synthases
/ metabolism
Prostaglandins
/ metabolism
Temperature
Thromboxanes
/ metabolism
Thymus Gland
/ drug effects
Aspirin
Celecoxib
Cyclooxygenase
Fish oil
Heart attack
Ibuprofen
Journal
Pharmacology & therapeutics
ISSN: 1879-016X
Titre abrégé: Pharmacol Ther
Pays: England
ID NLM: 7905840
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
20
04
2020
accepted:
30
06
2020
pubmed:
9
7
2020
medline:
16
11
2021
entrez:
9
7
2020
Statut:
ppublish
Résumé
Cyclooxygenase (COX)-1 and COX-2 are centrally important enzymes within the cardiovascular system with a range of diverse, sometimes opposing, functions. Through the production of thromboxane, COX in platelets is a pro-thrombotic enzyme. By contrast, through the production of prostacyclin, COX in endothelial cells is antithrombotic and in the kidney regulates renal function and blood pressure. Drug inhibition of COX within the cardiovascular system is important for both therapeutic intervention with low dose aspirin and for the manifestation of side effects caused by nonsteroidal anti-inflammatory drugs. This review focuses on the role that COX enzymes and drugs that act on COX pathways have within the cardiovascular system and provides an in-depth resource covering COX biology and pharmacology. The review goes on to consider the role of COX in both discrete cardiovascular locations and in associated organs that contribute to cardiovascular health. We discuss the importance of, and strategies to manipulate the thromboxane: prostacyclin balance. Finally within this review the authors discuss testable COX-2-hypotheses intended to stimulate debate and facilitate future research and therapeutic opportunities within the field.
Identifiants
pubmed: 32640277
pii: S0163-7258(20)30154-6
doi: 10.1016/j.pharmthera.2020.107624
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Cyclooxygenase Inhibitors
0
Prostaglandins
0
Thromboxanes
0
Cyclooxygenase 1
EC 1.14.99.1
Cyclooxygenase 2
EC 1.14.99.1
Prostaglandin-Endoperoxide Synthases
EC 1.14.99.1
Aspirin
R16CO5Y76E
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
107624Subventions
Organisme : British Heart Foundation
ID : RG/18/4/33541
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/19/6/34129
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/16/1/31699
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/15/47/31591
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/15/79/31777
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/17/40/33028
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Within the past 5 years, JAM is a member of the scientific advisory board of Antibe Therapeutics Inc. and has received contributions including ‘in kind’ from Gesynta Pharma AB, Actelion and Merck Sharp & Dohme Limited. Other authors declare no conflicts of interest to declare.